365betapp苹果版下载【首頁】

0431-81311122

媒体新闻

死磕强生!艾伯维巨资210亿美元抢婚Pharmacyclics

2015-03-05

来源:生物谷 2015-03-05

2015年3月5日讯 / --前面英国《金融时报(FT)》才爆出强生即将以超过170亿美元收购合作伙伴Pharmacyclics,这边艾伯维(AbbVie)宣布将以约210亿美元收购Pharmacyclics,以增强其肿瘤学药物管线。(相关阅读:一个产品要价$170亿?!传强生即将收购Pharmacyclics

艾伯维在声明中表示,该笔交易将由58%的现金和42%的AbbVie普通股组成。Pharmacyclics公司股东可以选择现金、AbbVie股票或2者组合。现金部分,艾伯维将支付每股261.25美元,比Pharmacyclics公司在纳斯达克股市周三收盘价溢价13%。AbbVie表示,希望通过现有资金及新的债务和股票相结合的方式完成收购交易。

艾伯维首席执行官Richard Gonzalez在声明中表示,Pharmacyclics公司研发的突破性抗癌药物Imbruvica不仅与该公司的肿瘤学管线完美互补,而且针对广泛的血液系统恶性肿瘤具有很强的临床疗效。目前,Imbruvica在美国已获批用于4种类型的血液癌症,在欧洲获批用于3种类型血液癌症。今年早些时候Pharmacyclics曾表示,Imbruvica本年度在美国市场的销售额预计将达到100亿美元。

强生与Pharmacyclics于2011年签署近10亿美元合作共同开发Imbruvica(ibrutinib),该药是一种首创的口服布鲁顿酪氨酸激酶(BTK)抑制剂,通过抑制肿瘤细胞复制和转移需要的布鲁顿酪氨酸激酶(BTK)而起到抗癌的作用。

在相当长的一段时期内,大型制药公司更多地是通过与较小的制药公司签署有利于双方共同开发产品的合作伙伴关系,而不是把小公司整体收购。然而,近年来,随着日益加剧的行业残酷竞争,这一方式已逐渐被“大鱼吃小鱼”甚至“大鱼吃大鱼”的形式取代。(力太生物.com)


英文原文:AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal

(Reuters) - Drugmaker AbbVie Inc (ABBV.N) said it will buy Pharmacyclics Inc (PCYC.O), the maker of blockbuster cancer drug Imbruvica, for about $21 billion to boost its oncology drugs pipeline.

AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq.

The deal will consist of about 58 percent cash and 42 percent AbbVie common stock. Pharmacyclics stockholders can elect cash, AbbVie stock or a combination, subject to proration, the company said in a statement.

"Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies," AbbVie's Chief Executive, Richard Gonzalez, said in a statement.

Sales of Imbruvica, which has U.S. approvals for four forms of blood cancer, are expected to touch $1 billion in the United States this year, Pharmacyclics has said earlier.

AbbVie said it expects to fund the transaction through a combination of existing cash, new debt and stock.

(Reporting by Supriya Kurane in Bengaluru; Editing by Gopakumar Warrier)


地址:吉林省长春市高新技术产业开发区锦湖大路1357(E)宝孚大厦4006室 电话:0431-81311122
版权所有:长春力太生物科技有限公司 吉ICP备14006071号-1

建站技术支持长春庞智科技